A cornerstone belief of ILADS and the chronic Lyme community is that the ELISA (enzyme-linked immunosorbent assay) screening test, which the CDC mandates as a necessary component of a true Lyme diagnosis, is unreliable and misses 35 percent of culture-proven Lyme disease.
